Adverse effects of short-acting beta-agonists: Potential impact when anti-inflammatory therapy is inadequate

Respirology

Volumn 9, Issue 2, 2004, Pages 215-221

  Wraight, Jonathan M ^a   Smith, Andrew D ^a   Cowan, Jan O ^a   Flannery, Erin M ^a   Herbison, G Peter ^a   Taylor, D Robin ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adverse effects; Asthma exacerbations; Beta agonist; Lung function; Tolerance

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL; SHORT ACTING DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BETA ADRENERGIC STIMULATION; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DETERIORATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; AREA UNDER CURVE; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED;

EID: 3142741559     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2004.00557.x     Document Type: Article

References (26)

1. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6.
2. Crane J, Pearce N, Flatt A et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; 1: 917-22.
3. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994; 343: 1379-82.
4. Drazen JM, Israel E, Boushey HA et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N. Engl. J. Med. 1996; 335: 841-7.
5. Taylor DR, Town GI, Herbison GP et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998; 53: 744-52.
6. Dennis SM, Sharp SJ, Vickers MR et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355: 1675-9.
7. Walters EH, Walters J. Inhaled short acting beta2-agonist use in athma: regular vs as needed treatment. Cochrane Database Syst. Rev. 2000; 4: CD001285.
8. Taylor DR, Sears MR, Herbison GP et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134-8.
9. Cloosterman SG, Bijl-Hofland ID, van Herwaarden CL et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. Chest 2001; 119: 1306-15.
10. Wahedna I, Wong CS, Wisniewski AF, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular beta 2-agonist treatment. Am. Rev. Respir. Dis. 1993; 148: 707-12.
11. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. 1996; 153: 65-9.
12. Cockcroft DW. Inhaled beta2-agonists and airway responses to allergen. J. Allergy Clin. Immunol. 1998; 102: S96-9.
13. Aldridge RE, Hancox RJ, Taylor DR et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 1459-64.
14. Hakonarson H, Herrick DJ, Grunstein MM. Mechanism of impaired beta-adrenoceptor responsiveness in atopic sensitized airway smooth muscle. Am. J. Physiol. 1995; 269: L645-52.
15. Koto H, Mak JC, Haddad EB et al. Mechanisms of impaired beta-adrenoceptor-induced airway relaxation by interleukin-1beta in vivo in the rat. J. Clin. Invest. 1996; 98: 1780-7.
16. Wang ZL, Bramley AM, McNamara A, Pare PD, Bai TR. Chronic fenoterol exposure increases in vivo and in vitro airway responses in guinea pigs. Am. J. Respir. Crit. Care Med. 1994; 149: 960-5.
17. Song P, Milanese M, Crimi E, Rehder K, Brusasco V. Allergen challenge of passively sensitized human bronchi alters M2 and beta2 receptor function. Am. J. Respir. Crit. Care Med. 1997; 155: 1230-4.
18. Tattersfield AE, Lofdahl CG, Postma DS et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-61.
19. Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose-response. J. Allergy Clin. Immunol. 1996; 97: 47-52.
20. Yan K, Salome C, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. Thorax 1983; 38: 760-5.
21. Jones SL, Kittelson J, Cowan JO et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am. J. Respir. Crit. Care Med. 2001; 164: 738-43.
22. Hancox RJ, Aldridge RE, Cowan JO et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur. Respir. J. 1999; 14: 283-7.
23. Hakonarson H, Herrick DJ, Serrano PG, Grunstein MM. Autocrine role of interleukin 1beta in altered responsiveness of atopic asthmatic sensitized airway smooth muscle. J. Clin. Invest. 1997; 99: 117-24.
24. Mak JC, Rousell J, Haddad EB, Barnes PJ. Transforming growth factor-beta1 inhibits beta2-adrenoceptor gene transcription. Naunyn Schmiedebergs Arch. Pharmacol. 2000; 362: 520-5.
25. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur. Respir. J. 2001; 17: 368-73.
26. Taylor DR, Sears MR, Cockcroft DW. The beta-agonist controversy. Med. Clin. North Am. 1996; 80: 719-48.